Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — H1 2022/23 Earnings Presentation
10 slides from Coloplast A/s Class B's earnings presentation, 2023
Slide 1: Conference call presentation H1 2022/23
Conference call presentation H1 2022/23 Kjell, Denmark Making life easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid Q2 2022/23, in line with expectations
NEW IMAGE Solid Q2 2022/23, in line with expectations Update picture Organic Reported ROIC growth EBIT margin 8% 28% * * 19% ** *before special items of 20 million DKK related to the Atos Medical integration **after tax and before special items 3 Kjell | Denmark
Slide 4: Strategic highlights from Strive25 – Sustainable growth leadership
Strategic highlights from Strive25 – Sustainable growth leadership Growth Innovation US Chronic Care Chronic Care – Clinical Performance Programme • Strong performance in the US Ostomy Care business, where Coloplast continues to • Luja™, the new male intermittent catheter with a Micro-hole Zone Tech
Slide 5: Solid organic growth of 8% in H1 2022/23 with solid momentum across business areas
Solid organic growth of 8% in H1 2022/23 with solid momentum across business areas and geographies, excluding China H1 2022/23 revenue by business area H1 2022/23 revenue by geography Business Reported revenue FY Organic growth Share of organic Geographic Reported revenue FY Organic growth Share of
Slide 6: H1 reported growth was up 14%, with ~6%-points impact from acquisition
H1 reported growth was up 14%, with ~6%-points impact from the Atos Medical acquisition and limited contribution from currencies H1 2022/23 Revenue development (DKKm) H1 2022/23 highlights • Organic growth was 8% or DKK 804 million, driven by: 1,495m DKK • Solid growth in Chronic Care across regions
Slide 7: Reported EBIT margin of 28% in H1, reflecting cost inflation and commercial activity
Reported EBIT margin of 28%1 in H1, reflecting an impact from cost inflation, increased level of commercial activity and amortisation costs H1 2022/23 EBIT margin development before special items (%) H1 2022/23 highlights • Gross margin was 67%, against 69% in H1 last year 31.3 -1.3 • Negative impac
Slide 8: Adj. FCF in H1 was DKK 1,137 million
Adj. FCF in H1 was DKK 1,137 million. Operating cash flow impacted by increased working capital; NWC-to-sales still expected at 24% for FY FCF development1 FCF development Comments H1 2022/23 highlights • Free cash flow for H1 2022/23 was an inflow of DKK 795 million compared to an outflow of DKK 9,
Slide 9: FY 2022/23 guidance – organic growth now around 8%
FY 2022/23 guidance – organic growth is now expected around 8% and the reported EBIT margin is now expected in the 28-29%* range Organic revenue growth Around 8% Reported revenue growth in DKK 8-9% Reported EBIT margin* 28-29% Effective tax rate Around 21% Capital expenditures Around 1.4 bn DKK *bef
Slide 10: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding